Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017–2023

Han, Yungang; Cheng, Meijin; Li, Zheng; Chen, Huihui; Xia, Shuang; Zhao, Yue; Wang, Yali; He, Wenyi; Wang, Wei

doi:10.1186/s12941-024-00677-4

Annals of Clinical Microbiology and Antimicrobials

Table 3 Main results of antibiotic susceptibility testing of clinical Nocardia isolates, derived from large-scale studies published beteen 2014 and 2023

From: Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017–2023

% of susceptible isolates
First author, year	AST method	Break-points	N of isolates	Amikacin	AUG	Ceftriaxone	Ciprofloxacin	Imipenem	Linezolid	Minocycline	Moxifloxacin	TMP-	Tobramycin
First author, year	AST method	Break-points	N of isolates	Amikacin	AUG	Ceftriaxone	Ciprofloxacin	Imipenem	Linezolid	Minocycline	Moxifloxacin	SMX
All Nocardia isolates
This study	BMD	CLSI	71	98.6	32.4	53.5	33.8	45.1	100	66.2	46.5	100	70.4
Hao Wang, 2022 [7]	BMD	CLSI	441	99.3	39.5	40.6	33.6	43.3	100	43.5	57.1	99.1	56.5
Hamdi, 2020 [8]	BMD	CLSI	2091	94	44	36	16	73	100	30	30	98	52
Schlaberg, 2014 [9]	BMD	CLSI	1299^b	95	37	56	17	49	100	22	40(n = 642)	98	55
Jing Yang, 2023 [10]	BMD	CLSI	130	100	35.4	48.5	17.7	43.9	100	63.9	48.5	97.7	74.6
N.farcinica (N.farcinica^a)				S	S	R	S	V	S	V	N/A	S	R
This study	BMD	CLSI	19	100	52.6	5.3	78.9	26.3	100	36.8	84.2	100	5.3
Hao Wang, 2022 [7]	BMD	CLSI	176	100	61.9	8.5	68.8	39.8	100	26.1	90.3	97.7	14.2
Hamdi, 2020 [8]	BMD	CLSI	319	100	96	3	49	83	100	7	76	99	1
Schlaberg, 2014 [9]	BMD	CLSI	204^b	100	76	3	43	33	100	5	79(n = 99)	99	0
Jing Yang, 2023 [10]	BMD	CLSI	27	100	66.7	7.4	59.3	29.7	100	29.6	92.6	92.6	14.8
N.abscessus (N.abscessus complex^a)				S	S	S	R	V	S	V	N/A	S	V
This study	BMD	CLSI	16	100	43.8	93.8	18.8	50	100	93.8	25	100	100
Hao Wang,2022 [7]	BMD	CLSI	54	100	48.1	90.7	18.5	46.3	100	79.6	29.6	100	87
Hamdi, 2020 [8]	BMD	CLSI	205	100	61	93	3	64	100	93	13	100	100
Schlaberg, 2014 [9]	BMD	CLSI	110^b	100	78	98	0	31	100	85	8(n = 39)	100	100
Jing Yang, 2023 [10]	BMD	CLSI	20	100	55	95	10	55	100	85	10	100	90
N.cyriacigeorgica (N.cyriacigeorgica^a)				S	R	S	R	S	S	V	N/A	S	S
This study	BMD	CLSI	13	100	0	76.9	0	61.5	100	61.5	7.7	100	100
Hao Wang, 2022 [7]	BMD	CLSI	126	100	6.3	66.7	2.4	58.7	100	42.9	18.3	100	96
Hamdi, 2020 [8]	BMD	CLSI	352	99	8	64	0	99	100	14	1	100	99
Schlaberg, 2014 [9]	BMD	CLSI	264^b	100	3	88	0	43	100	6	4(n = 128)	100	99
Jing Yang, 2023 [10]	BMD	CLSI	49	100	6.1	67.3	0	61.2	100	63.3	22.4	100	100
N.otitidiscaviarum (N.otitidiscaviarum^a)				S	R	R	S	R	S	V	N/A	S	V
This study	BMD	CLSI	5	100	0	0	20	0	100	80	60	100	100
Hao Wang, 2022 [7]	BMD	CLSI	26	100	11.5	3.8	7.7	3.8	100	61.5	46.2	100	57.7
Hamdi, 2020 [8]	BMD	CLSI	30	100	0	0	0	3	100	60	23	87	53
Schlaberg, 2014 [9]	BMD	CLSI	29^b	100	0	0	7	7	100	45	35 (n = 17)	100	62
Jing Yang, 2023 [10]	BMD	CLSI	14	100	7.1	7.1	7.2	0	100	61.5	57.1	100	78.6
N.wallacei (N.transvalensis complex^a)				R	V	S	S	V	S	V	N/A	S	R
This study	BMD	CLSI	3	100	66.7	66.7	66.7	33.3	100	33.3	100	100	33.3
Hao Wang, 2022 [7]	BMD	CLSI	11	72.7	63.6	63.6	72.7	36.4	100	27.3	90.9	100	9.1
Hamdi, 2020 [8]	BMD	CLSI	121	26	89	64	49	9	100	31	72	88	0
Schlaberg, 2014 [9]	BMD	CLSI	83	28	47	63	84	6	100	15	100	81	4
Jing Yang, 2023 [10]	BMD	CLSI	3	100	N/A	N/A	N/A	N/A	100	N/A	N/A	N/A	N/A

AST antimicrobial susceptibility testing, BMD broth microdilution, CLSI Clinical and Laboratory Standards Institute, N number, N/A not available
^aExpected antimicrobial susceptibility patterns of the most com monly isolated Nocardia species or species complexes provided by CLSI standard M62 [11]; the expected pattern “R/S/V” represents resistant/susceptible/variable
^bExcept for moxifloxacin

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com